Among them, SCCs are often characterized by FGFR1 amplifications that make these lung tumors dependent on FGF ligands in vitro and in vivo [29,30], suggesting FGF blockade by FGF trapping or FGFR inhibition by TK inhibitors might represent promising therapeutic strategies for lung cancer treatment. This evidence concerns the gene FGFR1 and lung carcinoma.